CGIM
CBIO

Cannon Global Investment Management’s Crescent Biopharma CBIO Stock Holding History

Cannon Global Investment Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,200
Closed -$187K – 68
2026
Q1 		$187K Buy
+10,200
New +$117K 0.37% 71

Other funds holding CBIO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

Cannon Global Investment Management's CBIO Position: Q2 2026 in Review

Cannon Global Investment Management sold out of Crescent Biopharma (CBIO) in Q2 2026, closing a stake of 10,200 shares — an estimated $187K sold.

Cannon Global Investment Management first reported a position in CBIO in Q1 2026 and held it in 1 quarter. The position peaked at $187K in Q1 2026. 8 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Cannon Global Investment Management reported no remaining Crescent Biopharma position as of Q2 2026 after selling out during the quarter.
  • Cannon Global Investment Management sold 10,200 Crescent Biopharma shares in Q2 2026, an estimated $187K.
  • Cannon Global Investment Management first reported a position in Crescent Biopharma in Q1 2026 and held it in 1 quarter.
  • Cannon Global Investment Management's Crescent Biopharma position peaked at $187K in Q1 2026.
  • 8 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Cannon Global Investment Management's 13F filing for Q2 2026, filed 30 Jul 2026.